Variation in access to hemophilia A treatments in the United States

Conclusions: How health plans covered HemA treatments varied. Plans added conditions on coverage beyond the FDA label roughly half the time. Conditions most often related to bleeding frequency. Variable coverage affects patients' access to treatment, and potentially has clinical implications on disease management and disease progression.PMID:34538215 | DOI:10.1080/13696998.2021.1982225

Source: Journal of Medical Economics - September 20, 2021 Category: Health Management Authors: Nikoletta M Margaretos Anisha M Patel Ari D Panzer Rachel C Lai Jennifer Whiteley James D Chambers Source Type: research